PEGylation of native disulfide bonds in proteins

被引:94
作者
Brocchini, Steve
Balan, Sibu
Godwin, Antony
Choi, Ji-Won
Zloh, Mire
Shaunak, Sunil
机构
[1] Univ London, Sch Pharm, Dept Pharmaceut, London WC1N 1AX, England
[2] Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England
[3] Hammersmith Hosp, Imperial Coll London, Fac Med, London W12 0NN, England
基金
英国惠康基金;
关键词
D O I
10.1038/nprot.2006.346
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
PEGylation has turned proteins into important new biopharmaceuticals. The fundamental problems with the existing approaches to PEGylation are inefficient conjugation and the formation of heterogeneous mixtures. This is because poly(ethylene glycol) (PEG) is usually conjugated to nucleophilic amine residues. Our PEGylation protocol solves these problems by exploiting the chemical reactivity of both of the sulfur atoms in the disulfide bond of many biologically relevant proteins. An accessible disulfide bond is mildly reduced to liberate the two cysteine sulfur atoms without disturbing the protein's tertiary structure. Site-specific PEGylation is achieved with a bis-thiol alkylating PEG reagent that sequentially undergoes conjugation to form a three- carbon bridge. The two sulfur atoms are re-linked with PEG selectively conjugated to the bridge. PEGylation of a protein can be completed in 24 h and purification of the PEG-protein conjugate in another 3 h. We have successfully applied this approach to PEGylation of cytokines, enzymes, antibody fragments and peptides, without destroying their tertiary structure or abolishing their biological activity.
引用
收藏
页码:2241 / 2252
页数:12
相关论文
共 32 条
[1]   The effects of arginine on refolding of aggregated proteins: not facilitate refolding, but suppress aggregation [J].
Arakawa, T ;
Tsumoto, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 304 (01) :148-152
[2]   CYSTEINE-17 OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IS PARTIALLY SOLVENT-EXPOSED [J].
ARAKAWA, T ;
PRESTRELSKI, SJ ;
NARHI, LO ;
BOONE, TC ;
KENNEY, WC .
JOURNAL OF PROTEIN CHEMISTRY, 1993, 12 (05) :525-531
[3]  
BALAN S, 2006, BIOCONJ CHEM
[4]   Disulfide bonds, their stereospecific environment and conservation in protein structures [J].
Bhattacharyya, R ;
Pal, D ;
Chakrabarti, P .
PROTEIN ENGINEERING DESIGN & SELECTION, 2004, 17 (11) :795-808
[5]   PEGylated antibodies and antibody fragments for improved therapy: a review [J].
Chapman, AP .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (04) :531-545
[6]   Structural and biophysical characterization of the 40 kDa PEG-interferon-α2a and its individual positional isomers [J].
Dhalluin, C ;
Ross, A ;
Leuthold, LA ;
Foser, S ;
Gsell, B ;
Müller, F ;
Senn, H .
BIOCONJUGATE CHEMISTRY, 2005, 16 (03) :504-517
[7]   Disulfide by Design™:: a computational method for the rational design of disulfide bonds in proteins [J].
Dombkowski, AA .
BIOINFORMATICS, 2003, 19 (14) :1852-1853
[8]   Refolding of low molecular weight urokinase plasminogen activator by dilution and size exclusion chromatography - A comparative study [J].
Fahey, EM ;
Chaudhuri, JB ;
Binding, P .
SEPARATION SCIENCE AND TECHNOLOGY, 2000, 35 (11) :1743-1760
[9]  
Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO
[10]  
2-W